Avalo Therapeutics, Inc. (AVTX) at Guggenheim 3rd Annual Healthcare Innovation Conference - AVALO THERAPEUTICS INC

Financial Performance:

• Raised $430 million in capital following positive Lotus trial data; end-of-September cash balance was $462 million.
• Current cash runway is sufficient to fund Phase 3 and 2 trials through 2029 without requiring additional fundraising.
• Capital allocation covers the upcoming second indication launch and the ABTX-010 engineered antibody program.

Guidance and Future Outlook:

• FDA and EMA regulatory feedback packages submitted; feedback expected by year-end to initiate Phase 3 trials in early 2027.
• ABTX-010 program (engineered antibody with extended PK) targeted for clinical entry in 2027.
• Second indication for ABTX-010 to be announced soon, expanding into a new therapeutic area.
• Long-term strategy anticipates the HS market evolving toward multiple mechanisms, combination therapies, and earlier patient intervention to prevent scarring.

Business Segments and Product Lines:

• ABTX-009 (Lotus): Primary focus; Phase 2 Lotus trial demonstrated consistent depth of response across two doses (600mg loading/300mg q4w vs. 300mg loading/150mg q2w) with no significant efficacy difference, supporting a 600/300mg dosing regimen for Phase 3.
• ABTX-010: Next-generation engineered anti-IL-1β antibody designed for extended half-life, high affinity, and potential abbreviated toxicology packages.
• Clinical Data: Lotus trial showed comparable efficacy in biologic-naive and prior biologic-exposed (TNF/IL-17) patients, indicating upstream mechanism efficacy; highest IHS4 response rates reported in recent data, targeting deep lesions and draining tunnels.

Market and Competitive Landscape:

• HS market dynamics mirroring IBD evolution: shifting toward diverse mechanisms (TNF declining, IL-17 dominant, IL-1β emerging) and combination therapies.
• Low current penetration of biologics (e.g., UCB reports ~10,000 patients) indicates significant growth potential; market size expected to expand as referral times shorten from 8-12 years to earlier intervention.
• Management asserts competitive advantage over AbbVie's alpha/beta bispecifics and J&J's bermelocumab due to superior safety profile, lack of IL-1α interference, and higher affinity.

Risks and Challenges:

• Elevated placebo response rates (~25% on HiSCR75) in current trial environment necessitate robust study powering and patient stratification in Phase 3.
• Regulatory dependency on achieving HiSCR75 as primary endpoint with step-down analysis to HiSCR50 and IHS4.
• Potential risks associated with bispecific mechanisms targeting IL-1α (hypothetical inflammation exacerbation, antibody "sink" effects in normal tissue).

Management Commentary and Tone:

• Tone is confident and strategic; management expresses high conviction in IL-1β as the central driver of HS pathology over IL-1α.
• Emphasizes capital efficiency and careful resource management while upsizing operations for parallel program execution.
• Views the drug's upstream mechanism as providing robust efficacy regardless of prior biologic exposure.

Analyst Questions and Answers:

• Q: Why IL-1β over IL-1α/bispecifics? A: Data shows IL-1α targeting (e.g., litikizumab) fails; bispecifics may draw antibodies into normal tissue or stoichiometrically hinder IL-1β binding.
• Q: Dose selection rationale? A: Both 300mg q2w and 600mg q4w regimens showed similar efficacy; 600/300mg selected for convenience and faster therapeutic range attainment.
• Q: Efficacy in TNF/IL-17 exposed patients? A: Efficacy was remarkably similar to naive patients, validating IL-1β's position upstream of the inflammatory cascade.
• Q: Phase 3 trial design? A: Proposing two pivotal studies to mitigate risk (similar to Moon Lake precedent); targeting 1,200–1,600 patients total with stratification to manage placebo rates.
• Q: Future indications? A: Requires clinical proof-of-concept and clear FDA pathways; targeting a large, less crowded market than HS with potential for combination therapy.

Other Key Points:

• Management highlights the critical role of the NLRP3 complex and IL-1β in driving neutrophil and macrophage activity in HS.
• Safety profile of Lotus was benign with no difference from placebo in SAEs, neutropenia, or infections.
• The company is prioritizing deeper lesion clearance (IHS4) as a key differentiator where IL-1β inhibition offers a distinct advantage.
• ABTX-010 aims to leverage high affinity (similar to the difference between lebrikizumab and tralokinumab in atopic dermatitis) to achieve superior clinical outcomes compared to existing IL-1β therapies.